Article
Maximize your asset value across the biopharma value chain
How to overcome the challenges of biotech companies to successfully maximize your asset value from clinical development to commercialization
Jan 03, 2023
Download

Demonstrating asset value is becoming more complex across therapeutic areas and impacting biotech, specialty, and larger pharma alike. Key stakeholders involved in the ultimate success of a drug, and their evidence needs, continue to evolve as the marketplace transforms from volume- to value-based performance.

With non-COVID post-pandemic launches underperforming by nearly 20% compared to pre-pandemic levels in the major markets and a tightening of payer budgets, biotech companies need to get savvier with their asset development and commercial readiness – even if they plan not to self-commercialize their product. How can biotech stakeholders define and build an actionable plan to maximize their asset value? Is an integrated evidence generation plan a mandatory requirement? Is self-commercialization the best way to retain value? Is omnichannel sales & marketing an imperative in the post-pandemic environment?

This article summarizes key insights from the panel discussion at the Swiss Biotech Insight event co-organized by IQVIA and the Swiss Biotech Association.

Included in the discussion 5 panelists across functions and including Biotech and biopharma executives, investor, and commercial and market access experts. Tom Baker, Senior Vice President, and General Manager at IQVIA Switzerland was the panel moderator. This article also includes some global trends presented by Aurelio Arias and Tom Baker during the event and relevant insights from IQVIA whitepapers.

Related solutions

Contact Us